Catabasis Pharmaceuticals Inc. today announced that data from a Phase 1 clinical trial of its lead development candidate, CAT-2003, will be presented at the American College of Cardiology’s 63rd Annual Scientific Session (ACC.14) in Washington, D.C. Catabasis’ chief medical officer, Joanne Donovan, M.D., Ph.D., will discuss the clinical data during the poster session from 9:45 to 10:30 a.m. EDT on Monday, March 31.
Help employers find you! Check out all the jobs and post your resume.
